<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="otherwise stated in a credit line to the data. Abstract" exact="Coronavirus disease 2019" post="(COVID-19) has shown high infection and mortality rates all"/>
 <result pre="as 2019 novel coronavirus (2019-nCoV), and the disease was named" exact="coronavirus disease 2019" post="(COVID-2019). The virus was renamed by the International Committee"/>
 <result pre="in China and it resulted in 774 deaths. In 2012," exact="Middle East respiratory syndrome" post="(MERS) which first emerged in Saudi Arabia resulted in"/>
 <result pre="6]. To date, there is no specific therapy to treat" exact="SARS-CoV-2 infection." post="Different drugs that were designed for other diseases including"/>
 <result pre="infections in mice model [38]. The reduced ACE2 levels following" exact="SARS-CoV infection" post="led to acute lung injury, and interestingly, the lung"/>
 <result pre="ACE2 (rhACE2) is being considered as a therapy to control" exact="SARS-CoV-2 infection." post="The idea is to use the soluble rhACE2 as"/>
 <result pre="therapy (ADT) to regulate androgen production have lowered risk for" exact="SARS-CoV-2 infection" post="compared with patients who did not receive ADT [86]."/>
 <result pre="could downregulate TMPRSS2 and this in turn could be lowering" exact="SARS-CoV-2 infection." post="It is suggested that ADT could be beneficial for"/>
 <result pre="did not affect morbidity or mortality in male mice following" exact="SARS-CoV infection" post="[63]. Based on this, it was suggested that the"/>
 <result pre="1 protein HSC Hematopoietic stem cell NTD N-terminal domain MERS" exact="Middle East respiratory syndrome" post="MGCA Meiotic germ cell antigen RBD Receptor binding domain"/>
 <result pre="MGCA Meiotic germ cell antigen RBD Receptor binding domain SARS" exact="Severe acute respiratory syndrome" post="coronavirus SRY Sex determining region Y TMPRSS2 Transmembrane protease/serine"/>
 <result pre="Factors associated with prolonged viral RNA shedding in patients with" exact="coronavirus disease 2019" post="(covid-19). Clin Infect Dis. 2020. 11.ZhengSFanJYuFFengBLouBZouQet al.Viral load dynamics"/>
 <result pre="X, Xiang YF. Can we use interleukin-6 (il-6) blockade for" exact="coronavirus disease 2019" post="(covid-19)-induced cytokine release syndrome (crs)? J Autoimmun. 2020;111. 67.WanSYiQFanSLvJZhangXGuoLet"/>
</results>
